A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF).

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Chronic heart failure
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Mar 2012 New source identified and integrated (European Clinical Trials Database).
    • 14 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top